1.445USD+0.35%Mkt Cap: 10.90M USDP/E: —Last update: 2026-06-01
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that i…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap10.90M USD
Enterprise Value-2.09M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-17.54M USD
Revenue/Share—
Last Price1.445 USD
Fiscal Year EndJun 2025
MR QuarterMar 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.32
PEG—
EV/EBITDA0.10
EV/Revenue—
P/S—
P/B0.69
EPS (TTM)-3.79
EPS (Forward)-4.41
52W Range
1.0603% of range12.10
52W High12.10 USD
52W Low1.060 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-92.27%
ROA-81.36%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.03M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-130.83%
Net Debt-12.80M USD
Net Debt/EBITDA0.63
Balance Sheet
Debt/Equity0.02
Current Ratio9.97
Quick Ratio9.02
Book Value/Sh2.069 USD
Cash/Share1.737 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 22, 2019
Splits
Last Split1:10
Split DateJul 7, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.7.54M
Float7.50M
Insiders0.36%
Institutions13.94%
Short Interest
Short Ratio1.8d
Short % Float2.52%
Short % Out.2.51%
Shares Short189.31K
Short (prev mo.)129.23K
Technical
SMA 501.452 (-0.5%)
SMA 2001.505 (-4.0%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)100.31K
Avg Vol (10d)92.05K
Technical Indicators
RSI (14)49.5
MACD-0.0133
MACD Signal-0.0167
MACD Hist.+0.0033
BB Upper1.723 USD
BB Middle1.458 USD
BB Lower1.193 USD
BB Width36.29%
ATR (14)0.1055 USD
Vol Ratio (20d)0.17x